Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting

Current Pharmaceutical Design

Volumn 12, Issue 22, 2006, Pages 2723-2747

  Meyer, A ^a   Auernheimer, J ^a   Modlinger, A ^a   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomaterial; Drug Targeting; Integrin ligands; Radiolabeling; RGD peptides; Structure based drug design; Tumor imaging

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; APCITIDE; ARGINYLGLYCYLASPARTIC ACID; BENZODIAZEPINE DERIVATIVE; BIOMATERIAL; CILENGITIDE; DMP 44; DOXORUBICIN; EPTIFIBATIDE; INTEGRIN; LIPOSOME; MOLYBDENUM 99; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PEPTIDE DERIVATIVE; PERTECHNETIC ACID TC 99M; POLYETHYLENEIMINE; ROXIFIBAN; SMALL INTERFERING RNA; TECHNETIUM 99M; TIROFIBAN; TRACER; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; BINDING SITE; BIOCOMPATIBILITY; CANCER; CELL ADHESION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; ISOTOPE LABELING; MATERIAL COATING; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VIRAL GENE THERAPY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INTEGRINS; NEOPLASMS; OLIGOPEPTIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 33746903085     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777947740     Document Type: Review

References (277)

1. Hynes RO. Integrins: A family of cell surface receptors. Cell 1987; 48: 549-54.
2. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
3. Xiong JP, Stehle T, Goodman SL, Arnaout MA. Integrins, cations and ligands: Making the connection. J Thromb Haemost 2003; 1: 1642-54.
4. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003; 2: 703-16.
5. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
6. Arnaout MA. Integrin structure: New twists and turns in dynamic cell adhesion. Immunol Rev 2002; 186: 125-40.
7. Arnaout MA. Structure and function of the leukocyte adhesion molecules cd11/cd18. Blood 1990; 75: 1037-50.
8. Mousa SA. Anti-integrin as novel drug-discovery targets: Potential therapeutic and diagnostic implications. Curr Opin Chem Biol 2002; 6: 534-41.
9. Gottschalk KE, Günther R, Kessler H. A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3). ChemBioChem 2002; 3: 470-3.
10. Travis MA, Humphries JD, Humphries MJ. An unraveling tale of how integrins are activated from within. Trends Pharmacol Sci 2003; 24: 192-7.
11. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, et al. A structural mechanism of integrin alpha(IIb)beta(3) "insideout" activation as regulated by its cytoplasmic face. Cell 2002; 110: 587-97.
12. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003; 301: 1720-5.
13. Li R, Gorelik R, Nanda V, Law PB, Lear JD, DeGrado WF, et al. Dimerization of the transmembrane domain of integrin alpha(IIb) subunit in cell membranes. J Biol Chem 2004; 279: 26666-73.
14. Adair BD, Yeager M. Three-dimensional model of the human platelet integrin alpha(IIb)beta(3) based on electron cryomicroscopy and X-ray crystallography. Proc Natl Acad Sci USA 2002; 99: 14059-64.
15. Liddington RC, Ginsberg MH. Integrin activation takes shape. J Cell Biol 2002; 158: 833-9.
16. Mould AP, Humphries MJ. Regulation of integrin function through conformational complexity: Not simply a knee-jerk reaction? Curr Opin Cell Biol 2004; 16: 544-51.
17. Carman CV, Springer TA. Integrin avidity regulation: Are changes in affinity and conformation underemphasized? Curr Opin Cell Biol 2003; 15: 547-56.
18. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, et al. Crystal structure of the extracellular segment of integrin alpha(v)beta(3). Science 2001; 294: 339-45.
19. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002; 110: 599-11.
20. Xiong JP, Stehle T, Goodman SL, Arnaout MA. New insights into the structural basis of integrin activation. Blood 2003; 102: 1155-9.
21. Humphries MJ, McEwan PA, Barton SJ, Buckley PA, Bella J, Mould AP. Integrin structure: Heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem Sci 2003; 28: 313-20.
22. Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol Rev 2002; 186: 141-63.
23. Li R, Mitra N, Gratkowski H, Vilaire G, Litvinov R, Nagasami C, et al. Activation of integrin alpha(IIb)beta(3) by modulation of transmembrane helix associations. Science 2003; 300: 795-8.
24. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: Differential regulation and roles in lymphocyte arrest under flow. Immunity 2000; 13: 759-69.
25. Smith JW, Piotrowicz RS, Mathis D. A mechanism for divalent cation regulation of beta 3-integrins. J Biol Chem 1994; 269: 960-7.
26. Schneider D, Engelman DM. Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins. J Biol Chem 2004; 279: 9840-6.
27. Gottschalk KE, Kessler H. A computational model of transmembrane integrin clustering. Structure (Camb) 2004; 12: 1109-16.
28. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-32.
29. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
30. Shattil SJ, Newman PJ. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood 2004; 104: 1606-15.
31. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 2003; 15: 572-82.
32. Grashoff C, Thievessen I, Lorenz K, Ussar S, Fässler R. Integrin-linked kinase: Integrin's mysterious partner. Curr Opin Cell Biol 2004; 16: 565-71.
33. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-21.
34. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-8.
35. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha(v)beta(3) for angiogenesis. Science 1994; 264: 569-71.
36. Ruegg C, Dormond O, Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: Which side to target? Endothelium 2002; 9: 151-60.
37. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 1994; 77: 477-8.
38. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha(v) beta(3) rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856-60.
39. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 1999; 112: 3985-93.
40. Kantlehner M, Schaffner P, Finsinger D, Meyer J, Jonczyk A, Diefenbach B, et al. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. ChemBioChem 2000; 1: 107-14.
41. Elicieri B, Stromblad S, Cheresh D. Integrin alpha(v) beta(3)-ligation requirement for a sustained map kinase signal essential for angiogenesis. FASEB J 1997; 11: A1290-A90.
42. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Anti-integrin alpha(v)beta(3) blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
43. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR, Jr., Schwartz RS, et al. Selective alpha(v)beta(3) integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha(v)beta(3) and osteopontin expression during neointima formation. Cardiovasc Res 1997; 36: 408-28.
44. Seemayer CA, Distler O, Kuchen S, Müller-Ladner U, Michel BA, Neidhart M, et al. Rheumatoid arthritis: New developments in the pathogenesis with special reference to synovial fibroblasts. Z Rheumatol 2001; 60: 309-18.
45. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-33.
46. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G , et al. Integrin alpha(v)beta(3) antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
47. Horton MA, Taylor ML, Arnett TR, Helfrich MH. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23c6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res 1991; 195: 368-75.
48. Gottschalk KE, Kessler H. The structures of integrins and integrinligand complexes: Implications for drug design and signal transduction. Angew Chem Int Ed Engl 2002; 41: 3767-74.
49. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin alpha(v)beta(3) complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-5.
50. Bork P, Doerks T, Springer TA, Snel B. Domains in plexins: Links to integrins and transcription factors. Trends Biochem Sci 1999; 24: 261-3.
51. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the a domain from the alpha subunit of integrin cr3 (cd11b/cd18). Cell 1995; 80: 631-8.
52. Arnaout MA, Goodman SL, Xiong JP. Coming to grips with integrin binding to ligands. Curr Opin Cell Biol 2002; 14: 641-51.
53. Marinelli L, Lavecchia A, Gottschalk KE, Novellino E, Kessler H. Docking studies on alpha(v)beta(3) integrin ligands: Pharmacophore refinement and implications for drug design. J Med Chem 2003; 46: 4393-404.
54. Müller G, Gurrath M, Kessler H. Pharmacophore refinement of gpIIb/ IIIa antagonists based on comparative studies of adhesiv cyclic and acyclic RGD peptides. J Comput Aided Mol Des 1994; 8: 709-30.
55. Feuston BP, Culberson JC, Duggan ME, Hartman GD, Leu CT, Rodan SB. Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin. J Med Chem 2002; 45: 5640-8.
56. Dechantsreiter MA, Planker E, Matha B, Lohof E, Hölzemann G, Jonczyk A, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J Med Chem 1999; 42: 3033-40.
57. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986; 44: 517-8.
58. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
59. Adler M, Lazarus RA, Dennis MS, Wagner G. Solution structure of kistrin, a potent platelet aggregation inhibitor and gp IIb-IIIa antagonist. Science 1991; 253: 445-8.
60. Saudek V, Atkinson RA, Pelton JT. Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 1991; 30: 7369-72.
61. Senn H, Klaus W. The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet gp IIb-IIIa receptor. J Mol Biol 1993; 232: 907-25.
62. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993; 268: 22874-82.
63. Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997; 36: 1374-89.
64. Kessler H, Gratias R, Hessler G, Müller G. Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by 'spatial screening'. Pure Appl Chem 1996; 68: 1201-05.
65. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J Am Chem Soc 1996; 118: 7461-72.
66. Wermuth J, Goodman SL, Jonczyk A, Kessler H. Stereoisomerism and biological activity of the selective and superactive alpha(v)beta(3) integrin inhibitor cyclo(-RGDfV-) and its retroinverso peptide. J Am Chem Soc 1997; 119: 1328-35.
67. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment p1. FEBS Lett 1991; 291: 50-4.
68. Gurrath M, Müller G, Kessler H, Aumailley M, Timpl R. Conformation/ activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992; 210: 911-21.
69. Haubner R, Schmitt W, Hölzemann G, Goodman SL, Jonczyk A, Kessler H. Cyclic RGD peptides containing beta-turn mimetics. J Am Chem Soc 1996; 118: 7881-91.
70. Shemyakin MM, Ovchinnikov YA, Ivanov VT. Topochemical investigations of peptide systems. Angew Chem Int Ed Engl 1969; 8: 492-9.
71. Peishoff CE, Ali FE, Bean JW, Calvo R, D'Ambrosio CA, Eggleston DS, et al. Investigation of conformational specificity at gpIIb/IIIa: Evaluation of conformationally constrained RGD peptides. J Med Chem 1992; 35: 3962-9.
72. Kopple KD, Baures PW, Bean JW, Dambrosio CA, Hughes JL, Peishoff CE, et al. Conformations of Arg-Gly-Asp containing heterodetic cyclic-peptides - solution and crystal studies. J Am Chem Soc 1992; 114: 9615-23.
73. Bach AC, Espina JR, Jackson SA, Stouten PFW, Duke JL, Mousa SA, et al. Type II' to type I beta-turn swap changes specificity for integrins. J Am Chem Soc 1996; 118: 293-94.
74. Lohof E, Planker E, Mang C, Burkhart F, Dechantsreiter MA, Haubner R, et al. Carbohydrate derivatives for use in drug design: Cyclic alpha(v)-selective RGD peptides. Angew Chem Int Ed Engl 2000; 39: 2761-64.
75. Gibson C, Sulyok GA, Hahn D, Goodman SL, Hölzemann G, Kessler H. Nonpeptidic alpha(v)beta(3) integrin antagonist libraries: On-bead screening and mass spectrometric identification without tagging. Angew Chem Int Ed Engl 2001; 40: 165-69.
76. Sulyok GA, Gibson C, Goodman SL, Hölzemann G, Wiesner M, Kessler H. Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alpha(v)beta(3) integrin antagonists. J Med Chem 2001; 44: 1938-50.
77. Dahmen C, Auernheimer J, Meyer A, Enderle A, Goodman SL, Kessler H. Improving implant materials by coating with nonpeptidic, highly specific integrin ligands. Angew Chem Int Ed Engl 2004; 43: 6649-52.
78. Goodman SL, Hölzermann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for alpha(v)beta(6), alpha(v)beta(5), and alpha(v)beta(3) integrins. J Med Chem 2002; 45: 1045-51.
79. Huang XZ, Wu JF, Cass D, Erle DJ, Corry D, Young SG, et al. Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin. J Cell Biol 1996; 133: 921-8.
80. Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The alpha(v) beta(6) integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol 1994; 127: 547-56.
81. Clark RA, Ashcroft GS, Spencer MJ, Larjava H, Ferguson MW. Re-epithelialization of normal human excisional wounds is associated with a switch from alpha(v)beta(5) to alpha(v)beta(6) integrins. Br J Dermatol 1996; 135: 46-51.
82. Duggan ME, Duong LT, Fisher JE, Hamill TG, Hoffman WF, Huff JR, et al. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. J Med Chem 2000; 43: 3736-45.
83. Meissner RS, Perkins JJ, Duong le T, Hartman GD, Hoffman WF, Huff JR, et al. Nonpeptide alpha(v)beta(3) antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide. Bioorg Med Chem Lett 2002; 12: 25-9.
84. Coleman PJ, Askew BC, Hutchinson JH, Whitman DB, Perkins JJ, Hartman GD, et al. Non-peptide alpha(v)beta(3) antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics. Bioorg Med Chem Lett 2002; 12: 2463-5.
85. Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong le T, et al. Nonpeptide alpha(v)beta(3) antagonists. 8. In vitro and in vivo evaluation of a potent alpha(v)beta(3) antagonist for the prevention and treatment of osteoporosis. J Med Chem 2003; 46: 4790-8.
86. Coleman PJ, Brashear KM, Askew BC, Hutchinson JH, McVean CA, Duong le T, et al. Nonpeptide alpha(v)beta(3) antagonists. Part 11: Discovery and preclinical evaluation of potent alpha(v)beta(3) antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004; 47: 4829-37.
87. Keenan RM, Miller WH, Kwon C, Ali FE, Callahan JF, Calvo RR, et al. Discovery of potent nonpeptide vitronectin receptor (alpha(v)beta(3)) antagonists. J Med Chem 1997; 40: 2289-92.
88. Keenan RM, Miller WH, Lago MA, Ali FE, Bondinell WE, Callahan JF, et al. Benzimidazole derivatives as arginine mimetics in 1, 4-benzodiazepine nonpeptide vitronectin receptor (alpha(v)beta(3)) antagonists. Bioorg Med Chem Lett 1998; 8: 3165-70.
89. Keenan RM, Miller WH, Barton LS, Bondinell WE, Cousins RD, Eppley DF, et al. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. Bioorg Med Chem Lett 1999; 9: 1801-6.
90. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000; 43: 22-6.
91. Kling A, Backfisch G, Delzer J, Geneste H, Graef C, Holzenkamp U, et al. Synthesis and SAR of n-substituted dibenzazepinone derivatives as novel potent and selective alpha(v)beta(3) antagonists. Bioorg Med Chem Lett 2002; 12: 441-6.
92. Peyman A, Scheunemann K, Will DW, Knolle J, Wehner V, Breipohl G, et al. Alpha(v)beta(3) antagonists based on a central thiophene scaffold. Bioorg Med Chem Lett 2001; 11: 2011-5.
93. Bubenik M, Meerovitch K, Bergeron F, Attardo G, Chan L. Thiophene-based vitronectin receptor antagonists. Bioorg Med Chem Lett 2003; 13: 503-6.
94. Lange UE, Backfisch G, Delzer J, Geneste H, Graef C, Hornberger W, et al. Synthesis of highly potent and selective hetaryl ureas as integrin alpha(v)beta3-receptor antagonists. Bioorg Med Chem Lett 2002; 12: 1379-82.
95. Penning TD, Russell MA, Chen BB, Chen HY, Desai BN, Docter SH, et al. Synthesis of cinnamic acids and related isosteres as potent and selective alpha(v)beta(3) receptor antagonists. Bioorg Med Chem Lett 2004; 14: 1471-6.
96. Ghosh S, Santulli RJ, Kinney WA, Decorte BL, Liu L, Lewis JM, et al. 1, 2, 3, 4-tetrahydroquinoline-containing alpha(v)beta(3) integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett 2004; 14: 5937-41.
97. De Corte BL, Kinney WA, Liu L, Ghosh S, Brunner L, Hoekstra WJ, et al. Piperidine-containing beta-arylpropionic acids as potent antagonists of alpha(v)beta(3)/alpha(v)beta(5) integrins. Bioorg Med Chem Lett 2004; 14: 5227-32.
98. Moitessier N, Henry C, Maigret B, Chapleur Y. Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: Docking of arginine-glycine-aspartic acid-like compounds into the alpha(v)beta(3) binding site. J Med Chem 2004; 47: 4178-87.
99. Craig D, Gao M, Schulten K, Vogel V. Structural insights into how the midas ion stabilizes integrin binding to an RGD peptide under force. Structure (Camb) 2004; 12: 2049-58.
100. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. Purification and functional characterization of integrin alpha(v)beta(5). An adhesion receptor for vitronectin. J Biol Chem 1990; 265: 11008-13.
101. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, et al. Involvement of integrins alpha(v)beta(3) and alpha(v)beta(5) in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9.
102. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha(v) integrins. Science 1995; 270: 1500-2.
103. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. Alpha(v)beta(3) and alpha(v)beta(5) integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 105-19.
104. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha(v) integrins. Cell 1998; 95: 507-19.
105. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, et al. Beta(3)-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-38.
106. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, et al. Inhibition of angiogenesis and tumor growth by sch221153, a dual alpha(v)beta(3) and alpha(v)beta(5) integrin receptor antagonist. Cancer Res 2001; 61: 2232-8.
107. Marinelli L, Gottschalk KE, Meyer A, Novellino E, Kessler H. Human integrin alpha(v)beta(5): Homology modeling and ligand binding. J Med Chem 2004; 47: 4166-77.
108. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8: 27-34.
109. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119: 1079-91.
110. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha(5) integrin-deficient mice. Development 1993; 119: 1093-105.
111. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha(5)beta(1) with the central cell-binding domain of fibronectin. Am J Pathol 2000; 156: 1345-62.
112. Cue D, Southern SO, Southern PJ, Prabhakar J, Lorelli W, Smallheer JM, et al. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of streptococcus pyogenes by blocking formation of integrin alpha(5)beta(1)-fibronectin-m1 protein complexes. Proc Natl Acad Sci USA 2000; 97: 2858-63.
113. Mould AP, Symonds EJ, Buckley PA, Grossmann JG, McEwan PA, Barton SJ, et al. Structure of an integrin-ligand complex deduced from solution X-ray scattering and site-directed mutagenesis. J Biol Chem 2003; 278: 39993-9.
114. Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrin alpha(5)beta(1) in complex with fibronectin. EMBO J 2003; 22: 4607-15.
115. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha(5)beta(1) integrin from a phage display library. J Cell Biol 1994; 124: 373-80.
116. Zhang L, Mattern RH, Malaney TI, Pierschbacher MD, Goodman M. Receptor-bound conformation of an alpha(5)beta(1) integrin antagonist by (15)N-edited 2D transferred nuclear overhauser effects. J Am Chem Soc 2002; 124: 2862-3.
117. Zimmermann D, Guthöhrlein EW, Malesevic M, Sewald K, Wobbe L, Heggemann C, et al. Integrin alpha(5)beta(1) ligands: Biological evaluation and conformational analysis. ChemBioChem 2005; 6: 272-76.
118. Smallheer JM, Weigelt CA, Woerner FJ, Wells JS, Daneker WF, Mousa SA, et al. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg Med Chem Lett 2004; 14: 383-7.
119. Marinelli L, Meyer A, Heckmann D, Lavecchia A, Novellino E, Kessler H. Ligand binding analysis for human a5β1 integrin: Strategies for designing new α5b1 integrin antagonists. J Med Chem 2005; 48: 4204-7.
120. Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 10: 1567-76.
121. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-62.
122. Plow EF, Ginsberg MH. Cellular adhesion: GpIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117-56.
123. Calzada MJ, Alvarez MV, Gonzalez-Rodriguez J. Agonist-specific structural rearrangements of integrin alpha(IIb)beta(3). Confirmation of the bent conformation in platelets at rest and after activation. J Biol Chem 2002; 277: 39899-908.
124. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997; 100: 91-5.
125. Hynes RO. Changing partners. Science 2003; 300: 755-6.
126. Li R, Bennett JS, Degrado WF. Structural basis for integrin alpha(IIb)beta(3) clustering. Biochem Soc Trans 2004; 32: 412-5.
127. Robinson A, O'Neill S, Moran N. Novel integrin-specific targets for anti-platelet therapies. Curr Pharm Des 2004; 10: 1603-9.
128. Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 2001; 3: 63-71.
129. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a gpIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9.
130. Feuston BP, Culberson JC, Hartman GD. Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem 2003; 46: 5316-25.
131. Claasen B, Axmann M, Meinecke R, Meyer B. Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha(IIb)beta(3) in native platelets than in liposomes. J Am Chem Soc 2005; 127: 916-9.
132. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
133. Egbertson MS, Cook JJ, Bednar B, Prugh JD, Bednar RA, Gaul SL, et al. Non-peptide gpIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem 1999; 42: 2409-21.
134. Scarborough RM, Gretler DD. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: Novel parenteral and potential oral antithrombotic agents. J Med Chem 2000; 43: 3453-73.
135. Coller BS. Platelet gpIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997; 100: 57-60.
136. Topol EJ, Byzova TV, Plow EF. Platelet gpIIb-IIIa blockers. Lancet 1999; 353: 227-31.
137. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, et al. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 1990; 195: 168-71.
138. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-73.
139. Hartman GD. Tirofiban hydrochloride. Drugs Future 1995; 20: 897-901.
140. Langer A. Second generation oral gpIIb/IIIa receptor blockade: Phase ii experience with roxifiban. J Am Coll Cardiol 2000; 35: 308.
141. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha(IIb)beta(3)) inhibitors. Blood 1998; 92: 3240-9.
142. Anderluh M, Cesar J, Stefanic P, Kikelj D, Janes D, Murn J, et al. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study. Eur J Med Chem 2005; 40: 25-49.
143. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004; 10: 1439-55.
144. Blum JE, Handmaker H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr Pharm Des 2002; 8: 1815-26.
145. Ezekowitz MD, Pope CF, Sostman HD, Smith EO, Glickman M, Rapoport S, et al. Indium-111 platelet scintigraphy for the diagnosis of acute venous thrombosis. Circulation 1986; 73: 668-74.
146. Knight LC, Primeau JL, Siegel BA, Welch MJ. Comparison of In-111-labeled platelets and iodinated fibrinogen for the detection of deep vein thrombosis. J Nucl Med 1978; 19: 891-4.
147. Knight LC, Maurer AH, Ammar IA, Epps LA, Dean RT, Pak KY, et al. Tc-99m antifibrin fab' fragments for imaging venous thrombi: Evaluation in a canine model. Radiology 1989; 173: 163-9.
148. Bautovich G, Angelides S, Lee FT, Greenough R, Bundesen P, Murray P, et al. Detection of deep venous thrombi and pulmonary embolus with technetium-99m-dd-3b6/22 anti-fibrin monoclonal antibody fab' fragment. J Nucl Med 1994; 35: 195-202.
149. Fichna J, Janecka A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug Chem 2003; 14: 3-17.
150. Barrett JA, Crocker AC, Damphousse DJ, Heminway SJ, Liu S, Edwards DS, et al. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. Bioconjug Chem 1997; 8: 155-60.
151. Barrett JA, Damphousse DJ, Heminway SJ, Liu S, Edwards DS, Looby RJ, et al. Biological evaluation of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: Effects of chelators on biological properties of [99mTc]chelator-peptide conjugates. Bioconjug Chem 1996; 7: 203-8.
152. Brouwers FM, Oyen WJ, Boerman OC, Barrett JA, Verheugt FW, Corstens FH, et al. Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist dmp444 spect in patients with infective endocarditis. Clin Nucl Med 2003; 28: 480-4.
153. Sakuma T, Sklenar J, Leong-Poi H, Goodman NC, Glover DK, Kaul S. Molecular imaging identifies regions with microthromboemboli during primary angioplasty in acute coronary thrombosis. J Nucl Med 2004; 45: 1194-200.
154. Tepmongkol S. Detection of acute cerebral ischaemia with Tc-99m apcitide scintigraphy. Neuroradiology 2002; 44: 819-21.
155. Francesconi LC, Zheng Y, Bartis J, Blumenstein M, Costello C, De Rosch MA. Preparation and characterization of [99TcO] apcitide: A technetium labeled peptide. Inorg Chem 2004; 43: 2867-75.
156. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled alpha(v)beta(3) integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999; 40: 1061-71.
157. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [18F]galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004; 15: 61-9.
158. Haubner R, Sulyok G, Weber W, Linke W, Bodenstein C, Wester HJ, et al. Synthesis and first in vivo evaluation of [I-123]aza-RGD-1: A radiolabeled RGD-mimetic for the noninvasive determination of alpha(v)beta3 integrin expression. Eur J Nucl Med 2001; 28: 1175.
159. Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, et al. Radiolabeled RGD-dtpa-Tyr(3)-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radio 2004; 19: 173-80.
160. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solidphase peptide synthesis and chemoselective oxime ligation. Chem Eur J 2003; 9: 2717-25.
161. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Non-invasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]-galacto-RGD. PLoS Med 2005; 2: 244-52.
162. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. Micropet imaging of brain tumor angiogenesis with 18F-labeled pegylated RGD peptide. Eur J Nucl Med Mol Imaging 2004; 31: 1081-9.
163. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005; 102: 191-201.
164. McQuade P, Knight LC, Welch MJ. Evaluation of 64Cu- and 125Iradiolabeled bitistatin as potential agents for targeting alpha(v)beta(3) integrins in tumor angiogenesis. Bioconjug Chem 2004; 15: 988-96.
165. Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571-9.
166. Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002; 78: 235-47.
167. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
168. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, et al. Anti-tumor efficacy of tumor vasculaturetargeted liposomal doxorubicin. J Control Release 2003; 91: 115-22.
169. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. Doxorubicin-formaldehyde conjugates targeting alpha(v)beta(3) integrin. Mol Cancer Ther 2004; 3: 1593-604.
170. Zarovni N, Monaco L, Corti A. Inhibition of tumor growth by intramuscular injection of cdna encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum Gene Ther 2004; 15: 373-82.
171. Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004; 6: 106-16.
172. Kossovsky N, R. Kossovsky; N. Kossovsky, eds.; Kluwer Academic Publishers: Netherlands, 1995; pp. 25-46.
173. Aubin JE. Bone stem cells. J Cell Biochem Suppl 1998; 30-31: 73-82.
174. Wlodarski KH. Properties and origin of osteoblasts. Clin Orthop 1990; 276-93.
175. Burg KJ, Porter S, Kellam JF. Biomaterial developments for bone tissue engineering. Biomaterials 2000; 21: 2347-59.
176. Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. Clin Orthop 2000; 371: 10-27.
177. Glowacki J, Mulliken JB. Demineralized bone implants. Clin Plast Surg 1985; 12: 233-41.
178. Tang L, Hung CP, Schuman EM. A role for the cadherin family of cell adhesion molecules in hippocampal long-term potentiation. Neuron 1998; 20: 1165-75.
179. Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ J Surg 2001; 71: 354-61.
180. Lacefield WR. Materials characteristics of uncoated/ceramiccoated implant materials. Adv Dent Res 1999; 13: 21-6.
181. Sykaras N, Iacopino AM, Marker VA, Triplett RG, Woody RD. Implant materials, designs, and surface topographies: Their effect on osseointegration. A literature review. Int J Oral Maxillofac Implants 2000; 15: 675-90.
182. Wataha JC. Materials for endosseous dental implants. J Oral Rehabil 1996; 23: 79-90.
183. Ducheyne P. Titanium and calcium phosphate ceramic dental implants, surfaces, coatings and interfaces. J Oral Implantol 1988; 14: 325-40.
184. Yang C. The effect of calcium phosphate implant coating on osteoconduction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 606-9.
185. Hulshoff JE, Jansen JA. Initial interfacial healing events around calcium phosphate (ca-p) coated oral implants. Clin Oral Implants Res 1997; 8: 393-400.
186. Hulshoff JE, van Dijk K, de Ruijter JE, Rietveld FJ, Ginsel LA, Jansen JA. Interfacial phenomena: An in vitro study of the effect of calcium phosphate (ca-p) ceramic on bone formation. J Biomed Mater Res 1998; 40: 464-74.
187. LeBaron RG, Athanasiou KA. Extracellular matrix cell adhesion peptides: Functional applications in orthopedic materials. Tissue Eng 2000; 6: 85-103.
188. Anselme K. Osteoblast adhesion on biomaterials. Biomaterials 2000; 21: 667-81.
189. Zamir E, Geiger B. Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci 2001; 114: 3583-90.
190. Geiger B, Bershadsky A. Assembly and mechanosensory function of focal contacts. Curr Opin Cell Biol 2001; 13: 584-92.
191. Petit V, Thiery JP. Focal adhesions: Structure and dynamics. Biol Cell 2000; 92: 477-94.
192. Pande G. The role of membrane lipids in regulation of integrin functions. Curr Opin Cell Biol 2000; 12: 569-74.
193. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-7.
194. Cowles EA, DeRome ME, Pastizzo G, Brailey LL, Gronowicz GA. Mineralization and the expression of matrix proteins during in vivo bone development. Calcif Tissue Int 1998; 62: 74-82.
195. Yu YM, Becvar R, Yamada Y, Reddi AH. Changes in the gene expression of collagens, fibronectin, integrin and proteoglycans during matrix-induced bone morphogenesis. Biochem Biophys Res Commun 1991; 177: 427-32.
196. Aronow MA, Gerstenfeld LC, Owen TA, Tassinari MS, Stein GS, Lian JB. Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990; 143: 213-21.
197. Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB. Expression of differentiated function by mineralizing cultures of chicken osteoblasts. Dev Biol 1987; 122: 49-60.
198. Stein GS, Lian JB, Gerstenfeld LG, Shalhoub V, Aronow M, Owen T, et al. The onset and progression of osteoblast differentiation is functionally related to cellular proliferation. Connect Tissue Res 1989; 20: 3-13.
199. Ganta DR, McCarthy MB, Gronowicz GA. Ascorbic acid alters collagen integrins in bone culture. Endocrinology 1997; 138: 3606-12.
200. Cowles EA, Brailey LL, Gronowicz GA. Integrin-mediated signaling regulates ap-1 transcription factors and proliferation in osteoblasts. J Biomed Mater Res 2000; 52: 725-37.
201. Rapuano BE, Wu C, MacDonald DE. Osteoblast-like cell adhesion to bone sialoprotein peptides. J Orthop Res 2004; 22: 353-61.
202. Schneider G, Burridge K. Formation of focal adhesions by osteoblasts adhering to different substrata. Exp Cell Res 1994; 214: 264-9.
203. Krause A, Cowles EA, Gronowicz G. Integrin-mediated signaling in osteoblasts on titanium implant materials. J Biomed Mater Res 2000; 52: 738-47.
204. Unger RE, Wolf M, Peters K, Motta A, Migliaresi C, James Kirkpatrick C. Growth of human cells on a non-woven silk fibroin net: A potential for use in tissue engineering. Biomaterials 2004; 25: 1069-75.
205. Peters K, Schmidt H, Unger RE, Otto M, Kamp G, Kirkpatrick CJ. Software-supported image quantification of angiogenesis in an in vitro culture system: Application to studies of biocompatibility. Biomaterials 2002; 23: 3413-9.
206. Unger RE, Krump-Konvalinkova V, Peters K, Kirkpatrick CJ. In vitro expression of the endothelial phenotype: Comparative study of primary isolated cells and cell lines, including the novel cell line hpmec-st1.6r. Microvasc Res 2002; 64: 384-97.
207. Krump-Konvalinkova V, Bittinger F, Unger RE, Peters K, Lehr HA, Kirkpatrick CJ. Generation of human pulmonary microvascular endothelial cell lines. Lab Invest 2001; 81: 1717-27.
208. Unger RE, Peters K, Wolf M, Motta A, Migliaresi C, Kirkpatrick CJ. Endothelialization of a non-woven silk fibroin net for use in tissue engineering: Growth and gene regulation of human endothelial cells. Biomaterials 2004; 25: 5137-46.
209. Unger RE, Peters K, Huang Q, Funk A, Paul D, Kirkpatrick CJ. Vascularization and gene regulation of human endothelial cells growing on porous polyethersulfone (pes) hollow fiber membranes. Biomaterials 2005; 26: 3461-9.
210. Wilson CJ, Clegg RE, Leavesley DI, Pearcy, MJ. Mediation of biomaterial-cell interactions by adsorbed proteins: A review. Tissue Engineering 2005; 11: 1-18.
211. Massia SP, Hubbell JA. Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials. J Biomed Mater Res 1991; 25: 223-42.
212. Fields GB, Lauer JL, Dori Y, Forns P, Yu YC, Tirrell M. Protein-like molecular architecture: Biomaterial applications for inducing cellular receptor binding and signal transduction. Biopolymers 1998; 47: 143-51.
213. Hern DL, Hubbell JA. Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J Biomed Mater Res 1998; 39: 266-76.
214. Huebsch JB, Fields GB, Triebes TG, Mooradian DL. Photoreactive analog of peptide fn-c/h-v from the carboxy-terminal heparinbinding domains of fibronectin supports endothelial cell adhesion and spreading on biomaterial surfaces. J Biomed Mater Res 1996; 31: 555-67.
215. Kobayashi H, Ikada Y. Corneal cell adhesion and proliferation on hydrogel sheets bound with cell-adhesive proteins. Curr Eye Res 1991; 10: 899-908.
216. Elbert DL, Hubbell JA. Conjugate addition reactions combined with free-radical cross-linking for the design of materials for tissue engineering. Biomacromolecules 2001; 2: 430-41.
217. Rouhi AM. Contemporary biomaterials. Chem Eng News 1999; 77: 51-59.
218. Lhoest JB, Detrait E, van den Bosch de Aguilar P, Bertrand P. Fibronectin adsorption, conformation, and orientation on polystyrene substrates studied by radiolabeling, XPS, and ToF SIMS. J Biomed Mater Res 1998; 41: 95-103.
219. Hlady VV, Buijs J. Protein adsorption on solid surfaces. Curr Opin Biotechnol 1996; 7: 72-7.
220. Altankov G, Grinnell F, Groth T. Studies on the biocompatibility of materials: Fibroblast reorganization of substratum-bound fibronectin on surfaces varying in wettability. J Biomed Mater Res 1996; 30: 385-91.
221. Pettit DK, Hoffman AS, Horbett TA. Correlation between corneal epithelial cell outgrowth and monoclonal antibody binding to the cell binding domain of adsorbed fibronectin. J Biomed Mater Res 1994; 28: 685-91.
222. Underwood PA, Steele JG, Dalton BA. Effects of polystyrene surface chemistry on the biological activity of solid phase fibronectin and vitronectin, analysed with monoclonal antibodies. J Cell Sci 1993; 104: 793-803.
223. Iuliano DJ, Saavedra SS, Truskey GA. Effect of the conformation and orientation of adsorbed fibronectin on endothelial cell spreading and the strength of adhesion. J Biomed Mater Res 1993; 27: 1103-13.
224. Lewandowska K, Pergament E, Sukenik CN, Culp LA. Cell-type-specific adhesion mechanisms mediated by fibronectin adsorbed to chemically derivatized substrata. J Biomed Mater Res 1992; 26: 1343-63.
225. Elbert DL, Hubbell JA. Surface treatments of polymers for biocompatibility. Annu Rev Mater Sci 1996; 26: 365-94.
226. Horbett TA, Lew KR. Residence time effects on monoclonal antibody binding to adsorbed fibrinogen. J Biomater Sci Polym Ed 1994; 6: 15-33.
227. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-3.
228. Feng Y, Mrksich M. The synergy peptide phsrn and the adhesion peptide RGD mediate cell adhesion through a common mechanism. Biochemistry 2004; 43: 15811-21.
229. Richman GP, Tirrell DA, Asthagiri AR. Quantitatively distinct requirements for signaling-competent cell spreading on engineered versus natural adhesion ligands. J Control Release 2005; 101: 3-12.
230. Jo S, Shin H, Mikos AG. Modification of oligo(poly(ethylene glycol) fumarate) macromer with a GRGD peptide for the preparation of functionalized polymer networks. Biomacromolecules 2001; 2: 255-61.
231. Lin YS, Wang SS, Chung TW, Wang YH, Chiou SH, Hsu JJ, et al. Growth of endothelial cells on different concentrations of Gly-Arg-Gly-Asp photochemically grafted in polyethylene glycol modified polyurethane. Artif Organs 2001; 25: 617-21.
232. Woerly S, Pinet E, de Robertis L, Van Diep D, Bousmina M. Spinal cord repair with phpma hydrogel containing RGD peptides (neurogel). Biomaterials 2001; 22: 1095-111.
233. Sofia S, McCarthy MB, Gronowicz G, Kaplan DL. Functionalized silk-based biomaterials for bone formation. J Biomed Mater Res 2001; 54: 139-48.
234. Quirk RA, Chan WC, Davies MC, Tendler SJ, Shakesheff KM. Poly(L-lysine)-GRGDS as a biomimetic surface modifier for poly(lactic acid). Biomaterials 2001; 22: 865-72.
235. Drumheller PD, Hubbell JA. Polymer networks with grafted cell adhesion peptides for highly biospecific cell adhesive substrates. Anal Biochem 1994; 222: 380-8.
236. Ho MH, Wang DM, Hsieh HJ, Liu HC, Hsien TY, Lai JY, et al. Preparation and characterization of RGD-immobilized chitosan scaffolds. Biomaterials 2005; 26: 3197-206.
237. Houseman BT, Mrksich M. The microenvironment of immobilized Arg-Gly-Asp peptides is an important determinant of cell adhesion. Biomaterials 2001; 22: 943-55.
238. Kao WJ, Hubbell JA, Anderson JM. Protein-mediated macrophage adhesion and activation on biomaterials: A model for modulating cell behavior. J Mater Sci Mater Med 1999; 10: 601-5.
239. Kao WJ, Hubbell JA. Murine macrophage behavior on peptide-grafted polyethyleneglycol-containing networks. Biotechnol Bioeng 1998; 59: 2-9.
240. Rajagopalan P, Marganski WA, Brown XQ, Wong JY. Direct comparison of the spread area, contractility, and migration of balb/c 3t3 fibroblasts adhered to fibronectin- and RGD-modified substrata. Biophys J 2004; 87: 2818-27.
241. Moghaddam MJ, Matsuda T. Molecular design of 3-dimensional artificial extracellular matrix: Photosensitive polymers containing cell adhesive peptide. J. Polym. Sci. Pol. Chem. 1993; 31: 1589-97.
242. Banerjee P, Irvine DJ, Mayes AM, Griffith LG. Polymer latexes for cell-resistant and cell-interactive surfaces. J Biomed Mater Res 2000; 50: 331-9.
243. Matsuda T, Kondo A, Makino K, Akutsu T. Development of a novel artificial matrix with cell adhesion peptides for cell culture and artificial and hybrid organs. ASAIO Trans 1989; 35: 677-9.
244. Irvine DJ, Ruzette AV, Mayes AM, Griffith LG. Nanoscale clustering of RGD peptides at surfaces using comb polymers. 2. Surface segregation of comb polymers in polylactide. Biomacromolecules 2001; 2: 545-56.
245. Walluscheck KP, Steinhoff G, Kelm S, Haverich A. Improved endothelial cell attachment on eptfe vascular grafts pretreated with synthetic RGD-containing peptides. Eur J Vasc Endovasc Surg 1996; 12: 321-30.
246. Holland J, Hersh L, Bryhan M, Onyiriuka E, Ziegler L. Culture of human vascular endothelial cells on an RGD-containing synthetic peptide attached to a starch-coated polystyrene surface: Comparison with fibronectin-coated tissue grade polystyrene. Biomaterials 1996; 17: 2147-56.
247. Hubbell JA. Biomaterials in tissue engineering. Biotechnology (NY) 1995; 13: 565-76.
248. Verrier S, Pallu S, Bareille R, Jonczyk A, Meyer J, Dard M, et al. Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process. Biomaterials 2002; 23: 585-96.
249. Siebers MC, ter Brugge PJ, Walboomers XF, Jansen JA. Integrins as linker proteins between osteoblasts and bone replacing materials. A critical review. Biomaterials 2005; 26: 137-46.
250. Hersel U, Dahmen C, Kessler H. RGD modified polymers: Biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003; 24: 4385-415.
251. Lieb E, Hacker M, Tessmar J, Kunz-Schughart LA, Fiedler J, Dahmen C, et al. Mediating specific cell adhesion to low-adhesive diblock copolymers by instant modification with cyclic RGD peptides. Biomaterials 2005; 26: 2333-41.
252. Kantlehner M, Finsinger D, Meyer J, Schaffner P, Jonczyk A, Diefenbach B, et al. Selektive RGD-vermittelte Adhäsion von Osteoplasten an Implantat-Oberflächen. Angew Chem 1999; 111: 587-90.
253. Delforge D, Art M, Gillon B, Dieu M, Delaive E, Raes M, et al. Automated solid-phase synthesis of cyclic peptides bearing a sidechain tail designed for subsequent chemical grafting. Anal Biochem 1996; 242: 180-6.
254. Healy KE, Rezania A, Stile RA. Designing biomaterials to direct biological responses. Ann N Y Acad Sci 1999; 875: 24-35.
255. Cook AD, Hrkach JS, Gao NN, Johnson IM, Pajvani UB, Cannizzaro SM, et al. Characterization and development of RGD-peptidemodified poly(lactic acid-co-lysine) as an interactive, resorbable biomaterial. J Biomed Mater Res 1997; 35: 513-23.
256. Massia SP, Hubbell JA. An RGD spacing of 440 nm is sufficient for integrin alpha(v)beta(3)-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation. J Cell Biol 1991; 114: 1089-100.
257. Neff JA, Tresco PA, Caldwell KD. Surface modification for controlled studies of cell-ligand interactions. Biomaterials 1999; 20: 2377-93.
258. Ito Y, Kajihara M, Imanishi Y. Materials for enhancing cell adhesion by immobilization of cell-adhesive peptide. J Biomed Mater Res 1991; 25: 1325-37.
259. Arnold M, Cavalcanti-Adam EA, Glass R, Blümmel J, Eck W, Kantlehner M, et al. Activation of integrin function by nanopatterned adhesive interfaces. ChemPhysChem 2004; 5: 383-8.
260. Meyer J, Nies B, Dard M, Hölzemann G, Kessler H, Kantlehner M, et al. Peptide and peptide mimetic conjugates with integrin-inhibitor properties. DE10040105 2000; 16.
261. Auernheimer J, Kessler H. Benzylprotected aromatic phosphonic acids for anchoring peptides on titanium. Bioorg Med Chem Lett 2006; 16: 271-3.
262. Auernheimer J, Zukowski D, Dahmen C, Kantlehner M, Enderle A, Goodman SL, et al. Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored RGD-peptides. ChemBioChem 2005; 6: 2034-40.
263. Johnson R, Harrison D, Tucci M, Tsao A, Lemos M, Puckett A, et al. Fibrous capsule formation in response to ultrahigh molecular weight polyethylene treated with peptides that influence adhesion. Biomed Sci Instrum 1997; 34: 47-52.
264. Schaffner P, Meyer J, Dard M, Wenz R, Nies B, Verrier S, et al. Induced tissue integration of bone implants by coating with bone selective RGD-peptides in vitro and in vivo studies. J Mater Sci Mater Med 1999; 10: 837-39.
265. Chinn JA, Sauter JA, Phillips RE, Jr., Kao WJ, Anderson JM, Hanson SR, et al. Blood and tissue compatibility of modified polyester: Thrombosis, inflammation, and healing. J Biomed Mater Res 1998; 39: 130-40.
266. Plant GW, Woerly S, Harvey AR. Hydrogels containing peptide or aminosugar sequences implanted into the rat brain: Influence on cellular migration and axonal growth. Exp Neurol 1997; 143: 287-99.
267. Kao WJ, Lee D. In vivo modulation of host response and macrophage behavior by polymer networks grafted with fibronectin-derived biomimetic oligopeptides: The role of RGD and PHSRN domains. Biomaterials 2001; 22: 2901-09.
268. Hubbell JA, Massia SP, Desai NP, Drumheller PD. Endothelial cell-selective materials for tissue engineering in the vascular graft via a new receptor. Biotechnology (N Y) 1991; 9: 568-72.
269. Eid K, Chen E, Griffith L, Glowacki J. Effect of RGD coating on osteocompatibility of plag-polymer disks in a rat tibial wound. J Biomed Mater Res 2001; 57: 224-31.
270. Ferris DM, Moodie GD, Dimond PM, Gioranni CW, Ehrlich MG, Valentini RF. RGD-coated titanium implants stimulate increased bone formation in vivo. Biomaterials 1999; 20: 2323-31.
271. Schliephake H, Scharnweber D, Dard M, Rossler S, Sewing A, Meyer J, et al. Effect of RGD peptide coating of titanium implants on periimplant bone formation in the alveolar crest. An experimental pilot study in dogs. Clin Oral Implants Res 2002; 13: 312-9.
272. Elmengaard B, Bechtold JE, Soballe K. In vivo study of the effect of RGD treatment on bone ongrowth on press-fit titanium alloy implants. Biomaterials 2005; 26: 3521-6.
273. Biltresse S, Attolini M, Dive G, Cordi A, Tucker GC, Marchand-Brynaert J. Novel RGD-like molecules based on the tyrosine template: Design, synthesis, and biological evaluation on isolated integrins alpha(v)beta(3)/alpha(IIb)beta(3) and in cellular adhesion tests. Bioorg Med Chem 2004; 12: 5379-93.
274. Wester HJ, Kessler H. Molecular targeting with peptides or peptide polymer conjugates: Just a question of size? J Nucl Med 2005; 46: 1940-45.
275. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004; 10(13): 1439-55.
276. Marcinkiewicz C. Functional characteristic of snake venom disintegrins: potential therapeutic implication. Curr Pharm Des 2005; 11(7): 815-27.
277. Vaidyanathan G, Zalutsky MR. Imaging drug resistance with radiolabeled molecules. Curr Pharm Des 2004; 10(24): 2965-79.